Cover Image

BEVACIZUMAB COMBINED WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN AS THE FIRST- LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA

Objective: Bevacizumab improved survival when added to chemotherapy for patients with metastatic colorectal cancer (mCRC). The aim of this study was to explore the efficacy and safety of Bevacizumab containing chemotherapy regimen in the treatment of patient with mCRC. Methods: From January 2010 to...

Full description

Saved in:

Bibliographic Details
Main Author:	Deyan Davidov (Author)
Format:	Book
Published:	Peytchinski Publishing, 2014-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2008)

OXALIPLATIN/5-FLUOROURACIL/LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan N. Davidov
Published: (2013)

CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2010)

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FIRST - LINE CHEMOTHERAPY
by: Deyan Davidov
Published: (2017)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
by: Suenaga M, et al.
Published: (2015)

FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES
by: Assia Konsoulova, et al.
Published: (2016)

The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity
by: Godefridus J. Peters, et al.
Published: (2024)

A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor
by: Qi Zhang, et al.
Published: (2022)

Survival benefit of preoperative hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin followed by hepatectomy for hepatocellular carcinoma
by: Zili Hu, et al.
Published: (2023)

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY
by: Deyan Davidov
Published: (2016)

Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
by: Zhao Y, et al.
Published: (2021)

The effective combination therapies with irinotecan for colorectal cancer
by: Yun Chai, et al.
Published: (2024)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy
by: Gao Z, et al.
Published: (2017)

THROMBOCYTOSIS AS PROGNOSTIC FACTOR FOR SURVIVAL IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED WITH FIRST- LINE CHEMOTHERAPY.
by: Deyan Davidov
Published: (2014)

A comparative study of combination treatments in metastatic 4t1 cells: everolimus and 5- fluorouracil versus lithium chloride and 5-fluorouracil
by: Dhiya Altememy, et al.
Published: (2022)

Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma
by: Haixia Zhang, et al.
Published: (2022)

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
by: Gerald HJ Mickisch, et al.
Published: (2011)

Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
by: Samantha Cohen, et al.
Published: (2019)

OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013)

Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer
by: Long-Zhuan Huang, et al.
Published: (2024)

OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
by: Deyan Davidov
Published: (2010)

Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters
by: Esther Oyaga-Iriarte, et al.
Published: (2019)

A Case of Long Term Survival in Woman with Metastatic Breast Cancer Treated with Trastuzumab
by: Deyan N. Davidov
Published: (2012)

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
by: Mohsin Hamid, et al.
Published: (2018)

Racial disparities in metastatic colorectal cancer outcomes revealed by tumor microbiome and transcriptome analysis with bevacizumab treatment
by: Lei Feng, et al.
Published: (2024)

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
by: Pau Riera, et al.
Published: (2020)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018)

Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center
by: Călin Căinap, et al.
Published: (2021)

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study
by: Zhuoling Zheng, et al.
Published: (2024)

Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer
by: Rulei Yang, et al.
Published: (2024)

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Ningning Liu, et al.
Published: (2020)

SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013)

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients
by: Hu GF, et al.
Published: (2016)

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
by: Toshiki Masuishi, et al.
Published: (2023)

Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report
by: Mingming Li, et al.
Published: (2019)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Ye Peng, et al.
Published: (2022)

Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma
by: Johanne Seguin, et al.
Published: (2024)

Immunotherapy regimens for metastatic colorectal carcinomas
by: Babar Bashir, et al.
Published: (2018)

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
by: Shinichiro Ryuge, et al.
Published: (2009)